Fri, Oct 31, 2014, 1:38 AM EDT - U.S. Markets open in 7 hrs 52 mins

Recent

% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, Inc. Message Board

fdaplayp 49 posts  |  Last Activity: Nov 18, 2013 2:29 PM Member since: Aug 19, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • This is your opportunity to minimum double or triple your money on upcoming Mega Phase 3 Results which coming any day now (4Q13) .
    This undiscovered Stock trading at $2.09 which is very close to all time low but what you should know is that Pharma Giant Glaxo (GSK) bought their 10 Million shares over $6++ and Management bought over $5++ and they never sold NONE OF THIS .

    Migalastat for the treatment of Fabry disease a rare disease is in Phase 3 which is Partnered with GSK . If the Phase 3 is positive then it has Blockbuster Potential and the Low Float Stock will run like ACAD or RMTI .

    Top‐Line 12‐Month Data from Phase 3 Fabry Monotherapy Study 011 in 4Q

    My Target is $15-20 quickly after Positive Phase 3 data .GLTA

    Amicus Therapeutics (FOLD)

    Market Cap : $103 M
    Cash $61 M
    Price : $2.09

    Shares Out 49.6 M ( Institutions & Managament holding 46 M Shares)

    Glaxo hiked its stake in Amicus to 19.9%. Glaxo made an investment of $18.6 million and bought 2,949,581 shares of Amicus at $6.30 per share. We note that as of March 31, 2012, Glaxo's holding in Amicus was 14.8%, representing an equity investment of $31 million. We believe that Glaxo's increased holding in Amicus reflects its confidence in Amicus' pipeline.

    Fabry is a rare inherited disease that affects between 5,000 and 10,000 people worldwide. It’s caused by the deficiency of a specific enzyme that breaks down a fat known as globotriaosylceramide (GL-3). Without the enzyme, GL-3 builds up in blood vessels, causing a host of side effects including severe kidney damage.

    Fabry is currently treated with enzyme-replacement therapies, such as agalsidase (Fabrazyme), which are administered intravenously. Amicus’ drug is a pill. Agalsidase, sold by Sanofi/Genzyme, is the only drug approved to treat Fabry in the U.S.

    -

  • This is your opportunity to minimum double or triple your money on upcoming Mega Phase 3 Results which coming any day now (4Q13) .
    This undiscovered Stock trading at $2.09 which is very close to all time low but what you should know is that Pharma Giant Glaxo (GSK) bought their 10 Million shares over $6++ and Management bought over $5++ and they never sold NONE OF THIS .

    Migalastat for the treatment of Fabry disease a rare disease is in Phase 3 which is Partnered with GSK . If the Phase 3 is positive then it has Blockbuster Potential and the Low Float Stock will run like ACAD or RMTI .

    Top‐Line 12‐Month Data from Phase 3 Fabry Monotherapy Study 011 in 4Q

    My Target is $15-20 quickly after Positive Phase 3 data .GLTA

    Amicus Therapeutics (FOLD)

    Market Cap : $103 M
    Cash $61 M
    Price : $2.09

    Shares Out 49.6 M ( Institutions & Managament holding 46 M Shares)

    Glaxo hiked its stake in Amicus to 19.9%. Glaxo made an investment of $18.6 million and bought 2,949,581 shares of Amicus at $6.30 per share. We note that as of March 31, 2012, Glaxo's holding in Amicus was 14.8%, representing an equity investment of $31 million. We believe that Glaxo's increased holding in Amicus reflects its confidence in Amicus' pipeline.

    Fabry is a rare inherited disease that affects between 5,000 and 10,000 people worldwide. It’s caused by the deficiency of a specific enzyme that breaks down a fat known as globotriaosylceramide (GL-3). Without the enzyme, GL-3 builds up in blood vessels, causing a host of side effects including severe kidney damage.

    Fabry is currently treated with enzyme-replacement therapies, such as agalsidase (Fabrazyme), which are administered intravenously. Amicus’ drug is a pill. Agalsidase, sold by Sanofi/Genzyme, is the only drug approved to treat Fabry in the U.S.

    -

  • Reply to

    Test

    by fdaplayp Nov 14, 2013 9:02 AM
    fdaplayp fdaplayp Nov 14, 2013 9:03 AM Flag

    s

  • Reply to

    Test

    by fdaplayp Nov 14, 2013 9:02 AM
    fdaplayp fdaplayp Nov 14, 2013 9:03 AM Flag

    s

  • Reply to

    Test

    by fdaplayp Nov 14, 2013 9:02 AM
    fdaplayp fdaplayp Nov 14, 2013 9:03 AM Flag

    s

  • Reply to

    Test

    by fdaplayp Nov 14, 2013 9:02 AM
    fdaplayp fdaplayp Nov 14, 2013 9:03 AM Flag

    s

  • Reply to

    Test

    by fdaplayp Nov 14, 2013 9:02 AM
    fdaplayp fdaplayp Nov 14, 2013 9:03 AM Flag

    s

  • Reply to

    Test

    by fdaplayp Nov 14, 2013 9:02 AM
    fdaplayp fdaplayp Nov 14, 2013 9:03 AM Flag

    s

  • Reply to

    Test

    by fdaplayp Nov 14, 2013 9:02 AM
    fdaplayp fdaplayp Nov 14, 2013 9:03 AM Flag

    s

  • Check it out guys you have the MEGA opportunity to buy this significantly underpriced stock at the bottom if you want to make money !

    AEZS has already a Drug on the Market which is partnered with pharma giant Merck (MRK) , this Product brings around $70 M in annual revenue to AEZS thats almost two times higher than current Market Cap .

    AEZS has another Drug awaiting FDA approval and muliple Cancer Drugs in Late Stage some of them have potential Blockbusters .

    I think AEZS has the potential for a runup to minimum to $4-5 before FDA decision in Mid 2014 . GL

    AEterna Zentaris (AEZS)

    Market Cap: $43 M
    Cash: $25 M
    Price: $1.35

    Shares Out: 32 M

    Annual Revenue :$ 70 M

    BIG PIPELINE :

    Macimorelin Acetate (AEZS-130)

    Diagnostic in adult growth hormonedeficiency (endocrinology) Awaiting FDA approval

    Product ..Zoptarelin Doxorubicin (AEZS-108)

    Endometrial cancer in Phase 3

    Tripl-negative breast cancer In Phase 2

    Castration-and taxane-resistant prostate cancer in Phase 2

    Refractory bladder cancer in Phase 2

    Ovarian cancer (completed) in Phase 2

    Product ..Ozarelix :

    Prostate cancer in Phase 2

    Product ..Macimorelin Acetate (AEZS-130)

    Therapeutic in cancer cachexia in Phase 2

    Product ..Perifosine

    Multiple cancers in Phase 2

    -

  • Check it out guys you have the MEGA opportunity to buy this significantly underpriced stock at the bottom if you want to make money !

    AEZS has already a Drug on the Market which is partnered with pharma giant Merck (MRK) , this Product brings around $70 M in annual revenue to AEZS thats almost two times higher than current Market Cap .

    AEZS has another Drug awaiting FDA approval and muliple Cancer Drugs in Late Stage some of them have potential Blockbusters .

    I think AEZS has the potential for a runup to minimum to $4-5 before FDA decision in Mid 2014 . GL

    AEterna Zentaris (AEZS)

    Market Cap: $43 M
    Cash: $25 M
    Price: $1.35

    Shares Out: 32 M

    Annual Revenue :$ 70 M

    BIG PIPELINE :

    Macimorelin Acetate (AEZS-130)

    Diagnostic in adult growth hormonedeficiency (endocrinology) Awaiting FDA approval

    Product ..Zoptarelin Doxorubicin (AEZS-108)

    Endometrial cancer in Phase 3

    Tripl-negative breast cancer In Phase 2

    Castration-and taxane-resistant prostate cancer in Phase 2

    Refractory bladder cancer in Phase 2

    Ovarian cancer (completed) in Phase 2

    Product ..Ozarelix :

    Prostate cancer in Phase 2

    Product ..Macimorelin Acetate (AEZS-130)

    Therapeutic in cancer cachexia in Phase 2

    Product ..Perifosine

    Multiple cancers in Phase 2

    -

  • Check it out guys and buy this significantly underpriced stock atthe bottom if you want to make money .GLTA

    This one is definitely one of the cheapest FDA Plays out there .

    Ticker: AEZS

    Market Cap: $42 M
    Cash: $25 M

    Shares Out: 32 M

    Aeterna Zentaris Inc. (AEZS) today announced that it has submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for its ghrelin agonist, macimorelin acetate (AEZS-130). Phase 3 data have demonstrated that the compound has the potential to become the first orally-approved product that induces growth hormone release to evaluate adult growth hormone deficiency ("AGHD"), with accuracy comparable to available intravenous and intramuscular testing procedures.

    David Dodd, President and CEO of Aeterna Zentaris, commented, "The submission of the NDA to the FDA is another major milestone in our strategy to bring macimorelin acetate to market as the first approved oral product for AGHD evaluation. We are also looking at potential expansion into traumatic brain injury victims and pediatrics which would represent significant growth opportunities for the Company. Finally, I would like to congratulate and thank all those involved in our drug development and regulatory affairs departments for this exciting accomplishment."
    -

  • Reply to

    Test

    by fdaplayp Nov 8, 2013 1:35 PM
    fdaplayp fdaplayp Nov 8, 2013 1:36 PM Flag

    s

  • Reply to

    Test

    by fdaplayp Nov 8, 2013 1:35 PM
    fdaplayp fdaplayp Nov 8, 2013 1:36 PM Flag

    s

  • Reply to

    Test

    by fdaplayp Nov 8, 2013 1:35 PM
    fdaplayp fdaplayp Nov 8, 2013 1:36 PM Flag

    s

  • Reply to

    Test

    by fdaplayp Nov 8, 2013 1:35 PM
    fdaplayp fdaplayp Nov 8, 2013 1:36 PM Flag

    s

  • Reply to

    Test

    by fdaplayp Nov 8, 2013 1:35 PM
    fdaplayp fdaplayp Nov 8, 2013 1:36 PM Flag

    s

  • Reply to

    Test

    by fdaplayp Nov 8, 2013 1:35 PM
    fdaplayp fdaplayp Nov 8, 2013 1:36 PM Flag

    s

  • A REAL Undiscovered Goldmine with Monster Upside Potential .. GLTA !!

    Summary :

    1) Laughable Market Cap of $99 M
    2) Cash for 12 Months ....... Profitability before Year End
    3) 4x Products launched in USA since December 2012
    4) 13x Products under review by FDA many of these will get FDA approval within 12 Months
    5) Another 1x ANDA filings coming before year end
    6) 72% of all Shares Outstanding held by Insiders & Institutions and still buying more
    7) Small Float of only ~11 Million Shares

    I think targets of $8-12 within 1-2 years is more realistic than Roth Capitals $3.50 .

    Ticker ( IG )

    Market Cap : $99 M
    Cash : $2.3 M
    Price : $2.30

    Shares Out : 43 M .....(31 Million Shares held by Big Investors)
    Float : 11 M

    IGI’s President and Chief Executive Officer, Jason Grenfell-Gardner, stated, “Our team has done a tremendous job this quarter. This quarter marks the fifth consecutive quarter of top line growth. Our net loss is rapidly approaching break even for the first time at IGI in over twenty-two quarters. We have solidified our market position in our first three IGI labeled topical pharmaceutical products, and we have successfully launched our fourth product, econazole nitrate cream 1%, which we acquired earlier this year, during the third quarter of 2013.” Mr. Grenfell-Gardner continued, “Our research and development team has now filed four ANDAs in 2013, which brings our total filings pending with the US FDA to twelve. Based on current IMS data, the addressable market for our pipeline of twelve ANDAs, pending approval at the US FDA is estimated at over $300 million. Our team is committed to our plan to file at least six ANDAs in 2013. We believe we are on track to at least double our 2012 total revenue and achieve profitability in 2013.”
    -

ONXX
124.700.00(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.